The isoprostanes in biology and medicine

Trends in Endocrinology and Metabolism

Volumn 12, Issue 6, 2001, Pages 243-247

  Praticò, Domenico ^a   Lawson, John A ^a   Rokach, Joshua ^b   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Florida Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; ISOPROSTANE DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

CHEMISTRY; DEGENERATIVE DISEASE; HUMAN; LIPID PEROXIDATION; METABOLISM; NOMENCLATURE; OXIDATIVE STRESS; REVIEW;

DINOPROST; F2-ISOPROSTANES; HUMANS; LIPID PEROXIDATION; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; TERMINOLOGY;

EID: 0035432159     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1043-2760(01)00411-8     Document Type: Review

References (63)

1. Pryor, W.A. et al. (1976) Auto-oxidation of polyunsaturated fatty acid: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. Lipilds 11, 370-379
2. Porter, N.A. and Funk, M.O. (1975) Peroxyl radical cyclization as a model for prostaglandin biosynthesis. J. Org. Chem. 40, 3614-3615
3. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radicalcatalyzed mechanism. Proc. Natl. Acad. Sci. U. S. A. 87, 9383-9387
4. 2-isoprostanes) are formed in situ in phospholipids. Proc. Nail. Acad. Sci. U. S. A. 89, 10721-10725
5. 3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 236, 467-472
6. Roberts, L.J. et al. (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273, 13605-13612
7. Morrow, J.D. et al. (1994) Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostames. J. Biol. Chem. 269, 4371-4326
8. Morrow, J.D. et al. (1996) Nonenzymaticfree radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J. Biol. Chem. 271, 23185-23190
9. Harrison, K.A. and Murphy, R.C. (1995) Isoleukotrienes are biologically active free radical products of lipid peroxidation. J. Biol. Chem. 270, 17273-17278
10. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103, 421-427
11. 2α. A novel strategy for the synthesis of isoprostanes. J. Am. Chem. Soc. 116, 10829-10830
12. 2α-I and its identification in biological fluids. Tetrahedron Lett. 37, 4849-4852
13. Rokach, J. et al. (1997) The isoprostanes: a perspective. Prostaglandins 54, 823-851
14. Taber, D.F. et al. (1997) A nomenclature system for the isoprostanes. Prostaglandins 53, 63-67
15. Rokach, J. et al. (1997) Nomenclature of isoprostanes: aproposal. Prostaglandins 54, 853-873
16. 2α-I: a novel index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. U. S. A. 95, 3449-3454
17. Praticò, D. et al. (1998) Enhanced lipid peroxidation in hepatic cirrhosis. J. Investig. Med. 46, 51-57
18. 2-isoprostane and 4-hydroxynonenal excretion in human bile of patients with biliary tract and pancreatic disorders. Am. J. Gastroenterol. 92, 2069-2072
19. 2α in pericardial fluid of patients with heart failure. Circulation 97, 1536-1539
20. 2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation In vivo. FASEB J. 12, 1777-1783
21. 2-isoprostanes concentration in probable AD. Neurology 52, 562-565
22. Montuschi, P. et al. (1998) 8-isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am. J. Respir. Crit. Care Med. 158, 1524-1527
23. Praticò, D. et al. (1997) Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100, 2028-2034
24. 2-isoprostanes) in carbon tetrachloride hepatotoxicity J. Clin. Invest. 90, 2502-2507
25. 2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol. 300, 3-17
26. 2-isoprostanes during the oxidative modification of low density lipoprotein. Biochem. Biophys. Res. Commun. 200, 338-343
27. 2α, is formed in vivo. Biochim. Biophys. Acta 1210, 244-248
28. 2α. J. Biol. Chem. 270, 9800-9808
29. 2-isoprostanes formed by free radical oxidation of arachidonic acid. J. Am. Soc. Mass Spectrom. 7, 490-499
30. 2α-VI, in human urine. J. Biol. Chem. 273, 29295-29301
31. Lawson, J.A. et al. (1999) Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274, 24441-24444
32. 2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry Basal levels in smokers and nonsmokers. Free Radic. Biol. Med. 20, 619-624
33. 2α excretion in man. J. Pharmacol. Exp. Ther. 275, 94-100
34. 2α by human monocytes. Discriminate production by reactive oxygen species and PG G/H S-2. J. Biol. Chem. 271, 8919-8924
35. 2-isoprostane formation. Br. J. Pharmacol. 118, 1285-1293
36. Reilly M. et al. (1996) Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94, 19-25
37. 2α-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158, 1709-1714
38. 2α, in the rat. J. Clin. Invest. 90, 136-141
39. 2α in isolated perfused rat lung. J. Appl. Physiol. 74, 460-465
40. 2α, in rabbit lung in situ. Am. J. Physiol. 263, H660-H663
41. 2α. Br. J. Pharmacol. 119, 1276-1280
42. Hoffman, S.W. et al. (1997) Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 28, 844-849
43. 2α on retinal vessels. Am. J. Physiol. 274, R1406-R1416
44. 2α is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271, 14916-14924
45. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 44, 155-163
46. 2α increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscl. Thromb. Vasc. Biol. 8, 1248-1256
47. 2 receptor. Circulation 101, 2833-2840
48. 2α. J. Biol. Chem. 272, 27147-27154
49. 2α-III, induce cardiomyocytes hypertrophy. J. Biol. Chem. 273, 22442-22452
50. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. New Engl. J. Med 332, 1198-1203
51. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368, 225-229
52. 2α and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation. Circulation 99, 224-229
53. 2-isoprostanes in hypercholesterolemia. Circulation 98, 2822-2828
54. 2a in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 96, 3314-3320
55. 2a generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation 95, 2492-2499
56. Breslow, J.L. (1996) Mouse models of atherosclerosis. Science 272, 685-688
57. Praticò, D. et al. (1998) Vitamin E suppresses isoprostane generation and reduces atherosclerosis in apolipoprotein E deficient mice. Nat. Med 4, 1189-1192
58. Praticò, D. and Delanty, N. (2000) Oxidative injury of the central nervous system - focus on Alzheimer's disease. Am. J. Med 109, 577-585
59. Delanty, N. and Dichter, M.A. (1998) Oxidative injury in the nervous system. Acta Neurol. Scand. 98, 145-153
60. Montine, T.J. et al. (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44, 410-413
61. 2α-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann. Neurol. 48, 809-812
62. Coyle, J.T. et al. (1986) The neurobiologic consequences of Down's syndrome. Brain Res. Bull. 16, 773-787
63. 2α-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann. Neurol. 48, 795-798